
1. Technology overview
Rhovica Neuroimaging AG is a Swiss neurosurgical visualization and monitoring company based at Weyermannsstrasse 36, 3008 Bern (register number CHE-360.994.571). It addresses the high misplacement rate of freehand external ventricular drain (EVD) insertion, which the company puts at up to 28 percent.
Its first product, SoNav, is an EVD catheter with integrated miniaturized sensors. The sensors capture live data from inside the brain so that the brain ventricles can be visualized at the bedside without external imaging equipment, and the catheter continues to support monitoring of elevated intracranial pressure after insertion. The target users are neurosurgeons treating severe trauma and brain bleeding. The company lists clinical advisors from Inselspital Bern, Mayo Clinic and University Hospital Verona.
2. Highlighted features & specifications
- Integrated sensors: Miniaturized sensors in the EVD catheter capture live data from inside the brain.
- Bedside visualization: The brain ventricles are shown in real time without external imaging.
- Guided placement: Supports fast and secure EVD insertion to cut misplacement and multiple passes.
- Pressure monitoring: Post-insertion monitoring helps detect elevated intracranial pressure emergencies.
- Emergency focus: Designed for severe trauma and brain bleeding.
3. Potential application
Bedside EVD placement in neurosurgical departments of tertiary hospitals in Vietnam. Emergency departments handling severe head trauma. Neuro-ICU monitoring of intracranial pressure after hemorrhage.
4. Benefits
Real-time ventricle visualization at the bedside without extra imaging equipment. Aims to reduce misplacement and repeated passes during EVD insertion. Continuous monitoring of intracranial pressure after placement from the same catheter. Fits neurosurgical emergency workflows for trauma and brain bleeding.
5. Market trends & opportunities
Neurocritical care units increasingly look for bedside tools that replace blind procedures with image guidance. Southeast Asian tertiary hospitals handling a high volume of trauma and stroke patients are a plausible market once regulatory approvals are in place.
6. Other information
Swiss company (Bern). Raised CHF 2.3 million in August 2025 in a round led by M2care; partnership with M2care announced December 2024. Awards: Ypsomed Innovation Award (January 2026), FutureHealth Basel Innovation Challenge (March 2026), Swiss Excellence Product Award (September 2025). The website lists no regulatory approval for SoNav; founding year not stated.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































